Akanda

Akanda FCF Growth

The Year-over-Year Free Cash Flow Growth of Akanda (AKAN) as of Oct 26, 2026 is -31.00 %. In the previous year, Year-over-Year Free Cash Flow Growth was -304.67 % — a change of -89.82% (higher).

FCF Growth

-31.00 %

YoY

-89.82%

Last updated:

Year-over-Year Free Cash Flow Growth of Akanda is 2025 -31.00 % . Year-over-Year Free Cash Flow Growth of Akanda was 2024 -304.67 % . It decreases by -89.82% higher compared to the previous year.

The Akanda FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2020
-34.88 USD
Jan 1, 2021
-298.16 USD
Jan 1, 2022
-65.14 USD
Jan 1, 2023
87.25 USD
Jan 1, 2024
-304.67 USD
Jan 1, 2025
-31.00 USD
The Akanda FCF Growth history
YEARFCF GrowthYoY
-31.00 %-89.82%
-304.67 %-449.20%
87.25 %-233.94%
-65.14 %-78.15%
-298.16 %+754.72%
-34.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Year-over-Year Free Cash Flow Growth of Akanda is -31.00 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Akanda since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Akanda historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Akanda

All Key Metrics — Akanda